202 related articles for article (PubMed ID: 26060045)
21. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.
Varga Z; Tubbs RR; Wang Z; Sun Y; Noske A; Kradolfer D; Bosshard G; Jochum W; Moch H; Öhlschlegel C
Breast Cancer Res Treat; 2012 Apr; 132(3):925-35. PubMed ID: 21698407
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.
Pu X; Shi J; Li Z; Feng A; Ye Q
Pathol Res Pract; 2015 Jun; 211(6):421-5. PubMed ID: 25818873
[TBL] [Abstract][Full Text] [Related]
23. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
24. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
Martin V; Botta F; Zanellato E; Molinari F; Crippa S; Mazzucchelli L; Frattini M
Histol Histopathol; 2012 Jun; 27(6):785-92. PubMed ID: 22473698
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
Ying JM; Liu XY; Guo L; Xie YQ; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
[TBL] [Abstract][Full Text] [Related]
26. Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm.
Park CK; Park JS; Kim HS; Rha SY; Hyung WJ; Cheong JH; Noh SH; Lee SK; Lee YC; Huh YM; Kim H
Oncotarget; 2016 Nov; 7(44):72099-72112. PubMed ID: 27765925
[TBL] [Abstract][Full Text] [Related]
27. Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus.
Ooi A; Zen Y; Ninomiya I; Tajiri R; Suzuki S; Kobayashi H; Imoto I; Dobashi Y
Pathol Int; 2010 Jun; 60(6):466-71. PubMed ID: 20518902
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer.
Vora HH; Patel NA; Thakore PM; Shukla SN
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):653-60. PubMed ID: 25789532
[TBL] [Abstract][Full Text] [Related]
29. [Immunohistochemical characteristics of triple negative/basal-like breast cancer].
Pala EE; Bayol Ü; Cumurcu S; Keskın E
Turk Patoloji Derg; 2012; 28(3):238-44. PubMed ID: 23011826
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation.
Kazakov DV; Ivan D; Kutzner H; Spagnolo DV; Grossmann P; Vanecek T; Sima R; Kacerovska D; Shelekhova KV; Denisjuk N; Hillen U; Kuroda N; Mukensnabl P; Danis D; Michal M
Am J Dermatopathol; 2009 May; 31(3):236-47. PubMed ID: 19384064
[TBL] [Abstract][Full Text] [Related]
31. EGFR expression and activation are common in HER2 positive and triple-negative breast tumours.
Koletsa T; Kotoula V; Karayannopoulou G; Nenopoulou E; Karkavelas G; Papadimitriou CS; Kostopoulos I
Histol Histopathol; 2010 Sep; 25(9):1171-9. PubMed ID: 20607659
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast.
Shao MM; Zhang F; Meng G; Wang XX; Xu H; Yu XW; Chen LY; Tse GM
Histopathology; 2011 Aug; 59(2):264-73. PubMed ID: 21884205
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor as an adverse survival predictor in squamous cell carcinoma of the penis.
Silva Amancio AM; Cunha IW; Neves JI; Quetz JD; Carraro DM; Rocha RM; Zequi SC; Cubilla AL; da Fonseca FP; Lopes A; Cunha MD; Lima MV; Vassallo J; Guimarães GC; Soares FA
Hum Pathol; 2017 Mar; 61():97-104. PubMed ID: 27864120
[TBL] [Abstract][Full Text] [Related]
34. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical and oncogenetic analyses of the esophageal basaloid squamous cell carcinoma in comparison with conventional squamous cell carcinomas.
Imamhasan A; Mitomi H; Saito T; Hayashi T; Takahashi M; Kajiyama Y; Yao T
Hum Pathol; 2012 Nov; 43(11):2012-23. PubMed ID: 22607702
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma.
Friedrich C; von Bueren AO; Kolevatova L; Bernreuther C; Grob T; Sepulveda-Falla D; van den Boom L; Westphal M; Simon R; Glatzel M
Childs Nerv Syst; 2016 Feb; 32(2):281-90. PubMed ID: 26686534
[TBL] [Abstract][Full Text] [Related]
37. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3,149 Chinese patients.
Han X; Shi Y; Ma L; Lyu Z; Yang H; Yao J; Li J; Li B; Qin Y
Chin Med J (Engl); 2014; 127(2):246-53. PubMed ID: 24438611
[TBL] [Abstract][Full Text] [Related]
38. Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients.
Kim Y; Kim J; Lee HD; Jeong J; Lee W; Lee KA
PLoS One; 2013; 8(10):e79014. PubMed ID: 24205362
[TBL] [Abstract][Full Text] [Related]
39. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
[TBL] [Abstract][Full Text] [Related]
40. Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis.
Tsiambas E; Mastronikolis NS; Lefas AY; Georgiannos SN; Ragos V; Fotiades PP; Tsoukalas N; Kavantzas N; Karameris A; Peschos D; Patsouris E; Syrigos K
In Vivo; 2017; 31(4):641-648. PubMed ID: 28652432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
